Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Carafate advertising

Executive Summary

The company met with FDA Division of Drug Advertising and Labeling on April 10 to discuss remedial actions that the agency requested in a March 14 reg letter. In objecting to Marion's continuing promotions that imply that Carafate is useful for NSAID-induced ulcers and other unapproved uses. FDA told the firm that it should send a corrective letter to every U.S. physician and run corrective ads in medical journals ("The Pink Sheet" March 27, p. 9).

You may also be interested in...



Podcast: The Week In European Consumer Health Industry News, 8 March 2021

HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.

The Ins And Outs Of The EU's Approach To COVID-19 Vaccine Procurement & Exports

EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's  COVID-19 vaccine.

Harmonization Of The EU Regulatory Compliance Role: Many PRRC Issues To Be Clarified

Efforts are underway to create a harmonized approach among Persons Responsible for Regulatory Compliance who play a pivotal role in meeting the requirements of the EU MDR and IVDR. And liability issues are high on the agenda.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel